Please Wait.....
Report
Atrial Fibrillation Market Report and Forecast 2025-2034
Market Report I 2025-06-20 I 400 Pages I EMR Inc.
The atrial fibrillation market was valued at USD 17.54 Billion in 2024, driven by the rising technological advancements across the 8 major markets. The market is anticipated to grow at a CAGR of 6.80% during the forecast period of 2025-2034, with the values likely to reach USD 33.86 Billion by 2034.
Atrial Fibrillation Market Overview
Atrial fibrillation is an abnormal heart rhythm condition that can result in an irregular and rapid heartbeat, thereby reducing blood flow to the body. It has several risks associated with it, including stroke, heart failure, and other related conditions. Atrial fibrillation occurs when heart's electrical signals become disorganized, thus resulting in uncoordinated atrial contractions. It mostly affects the elderly but can happen at any age. The market growth is driven by an increased prevalence of atrial fibrillation, better treatment options, higher health awareness, and improved diagnostic technology. As a result, there is an increasing demand for both pharmacological and non-pharmacological therapies to manage the condition, with significant market opportunities for innovative treatments and technologies.
Atrial Fibrillation Market Growth Drivers
Rising Incidence of Atrial Fibrillation to Drive the Market Growth
The increasing prevalence of atrial fibrillation, particularly in the elderly population is a key factor in market growth. According to the Centers for Disease Control and Prevention's May 2024 data, atrial fibrillation is expected to affect 12.1 million people in the United States by 2030. The high prevalence is increasing due to various lifestyle factors such as high blood pressure, obesity, and diabetes.
Technological Advancements Enhance the Atrial Fibrillation Market Value
Continuous innovation in medical devices and treatment techniques is enhancing the growth of the market. The advancements include the integration of robotic-assisted catheter ablation and advanced pacemakers, enhancing the accuracy and success rate of treatments. These innovations offer better outcomes for patients but also drive market expansion as healthcare providers adopt the latest technologies.
Atrial Fibrillation Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rising Adoption of Wearable Devices
The popularity of wearable devices in the market to monitor continuous heart rhythm is growing rapidly. Devices such as smartwatches or mobile ECG monitors allow patients to track real-time heart rate and alert for early detection of atrial fibrillation episodes. This trend is transforming the management of atrial fibrillation, allowing both the patient and the physician to monitor the condition more efficiently and remotely, resulting in earlier intervention and better results.
Advancements in Catheter Ablation to Boost Atrial Fibrillation Market Value
Catheter ablation, a non-pharmacological treatment for atrial fibrillation, has seen significant advancements in success rates and safety. New technologies such as robotic-assisted procedures, high-definition imaging techniques, and improved mapping systems have enhanced precision during the procedure. These innovations are making catheter ablation a more effective and preferred treatment for many patients, driving the atrial fibrillation market growth.
Preference for Personalized Treatment Approaches to Augment Atrial Fibrillation Market Demand
Genetic testing and personalized medicine are revolutionizing treatment plans. Care providers are using genetic and biomarker information for providing individualized treatments to patients. This customized approach ensures that treatments are more effective, minimizing adverse reactions and enhancing patient outcomes.
Increasing Demand for Minimally Invasive Procedures to Impact Atrial Fibrillation Market Size Positively
The demand for minimally invasive procedures is a key trend in the market, driven by the preference for treatments that offer shorter recovery times, lower risks, and minimal discomfort. Procedures such as percutaneous catheter ablation and left atrial appendage closure devices are gaining popularity due to their efficiency and minimally invasive nature among patients and healthcare providers.
Atrial Fibrillation Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
- Pharmacological Treatment
??- Anticoagulants
??- Antiarrhythmic Drugs
- Non-Pharmacological Treatment
??- Catheter Ablation
??- Radiofrequency
??- HIFU
??- Cryoablation
??- Microwave
??- Laser
- Maze Surgery
- Electric Cardioversion
Market Breakup by Route of Administration
- Oral
- Intravenous
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Market Breakup by Region
- United States
- United Kingdom
??- Germany
??- France
??- Italy
??- Spain
- Japan
- India
Atrial Fibrillation Market Share
Segmentation Based on Treatment Type to Witness Substantial Growth
Based on the type of treatment, the market is segmented into pharmacological treatment and non-pharmacological treatment. Non-pharmacological treatments, especially catheter ablation, are expected to have a significant share in the market. It can be accredited to technological advancements that have improved the safety, success rates, and accessibility of these procedures. As patients look for long-term solutions, non-pharmacological treatments are increasingly preferred, allowing this segment to capture a larger share of the market.
Atrial Fibrillation Market Analysis by Region
Based on region, the market is divided into the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. The market in the United States is driven by a high prevalence of the condition. Moreover, factors such as aging population, advanced treatment, robust health infrastructure, and appropriate reimbursement policies. In the United Kingdom, the market is witnessing growth, driven by increased awareness, better health access, and government support in terms of health and cardiovascular.
Leading Players in the Atrial Fibrillation Market
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
AtriCure Inc.
AtriCure was founded in 2000, and it is headquartered in Ohio, USA. The company is a major player in the market and specializes in the development of medical devices for atrial fibrillation treatment.
Boehringer Ingelheim GmbH
Boehringer Ingelheim, established in 1885 and based in Ingelheim, Germany, is a global leader in the healthcare industry, especially in heart disease therapies. In the atrial fibrillation market, the company provides Pradaxa (dabigatran), an anticoagulant to prevent stroke in patients. The company is expanding its portfolio with effective therapies for better patient outcomes in atrial fibrillation management.
Boston Scientific Corporation
Boston Scientific is a global leader in medical devices, founded in 1979 and headquartered in Marlborough, Massachusetts. The company offers innovative treatments, including the Watchman Device, designed to reduce stroke risk by closing the left atrial appendage in atrial fibrillation patients. It is committed to advancing heart disease management with cutting-edge technologies for improved patient outcomes.
Bristol Myers Squibb Corporation
Bristol Myers Squibb (BMS), founded in 1858 and headquartered in New York, is a global leader in biopharmaceuticals, focusing on areas like cardiovascular diseases. In the atrial fibrillation market, it offers Eliquis (apixaban), an anticoagulant that reduces stroke risk in patients. The company's ongoing research enhances its commitment to providing innovative treatments for better atrial fibrillation management and patient outcomes.
Other key players in the market include Cardio Focus Inc., Sanofi, Biosense Webster Inc., Abbott, Johnsons & Johnson Services, Inc., and Bayer AG.
Key Questions Answered in the Atrial Fibrillation Market Report
- What was the atrial fibrillation market value in 2024?
- What is the atrial fibrillation market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on treatment type?
- What is the market segmentation based on the route of administration?
- What is the market breakup based on the distribution channel?
- What is the market breakup based on end users?
- What major factors aid the atrial fibrillation market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the atrial fibrillation market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Atrial Fibrillation Market Overview - 8 Major Markets
3.1 Atrial Fibrillation Market Historical Value (2018-2024)
3.2 Atrial Fibrillation Market Forecast Value (2025-2034)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Atrial Fibrillation Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Atrial Fibrillation Market - Epidemiology Scenario and Forecast - 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2018-2034)
7.2 Prevalence, by Country
7.2.1 United States
7.2.2 United Kingdom
7.2.3 Germany
7.2.4 France
7.2.5 Italy
7.2.6 Spain
7.2.7 India
7.2.8 Japan
7.3 Diagnosed Cases, by Country
7.3.1 United States
7.3.2 United Kingdom
7.3.3 Germany
7.3.4 France
7.3.5 Italy
7.3.6 Spain
7.3.7 India
7.3.8 Japan
7.4 Treatment Seeking Rate, by Country
7.4.1 United States
7.4.2 United Kingdom
7.4.3 Germany
7.4.4 France
7.4.5 Italy
7.4.6 Spain
7.4.7 India
7.4.8 Japan
8 Atrial Fibrillation Market Landscape - 8 Major Markets
8.1 Atrial Fibrillation Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Atrial Fibrillation Market: Product Landscape
8.2.1 Analysis by Treatment Type
8.2.2 Analysis by Route of Administration
9 Atrial Fibrillation Market Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Atrial Fibrillation Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter's Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Atrial Fibrillation Market Segmentation (218-2034) - 8 Major Markets
12.1 Atrial Fibrillation Market (2018-2034) by Treatment Type
12.1.1 Market Overview
12.1.2 Pharmacological Treatment
12.1.2.1 Anticoagulants
12.1.2.2 Antiarrhythmic Drugs
12.1.3 Non-Pharmacological Treatment
12.1.3.1 Catheter Ablation
12.1.3.1.1 Radiofrequency
12.1.3.1.2 HIFU
12.1.3.1.3 Cryoablation
12.1.3.1.4 Microwave
12.1.3.1.5 Laser
12.1.3.2 Maze Surgery
12.1.3.3 Electric Cardioversion
12.2 Atrial Fibrillation Market (2018-2034) by Route of Administration
12.2.1 Market Overview
12.2.2 Oral
12.2.3 Intravenous
12.2.4 Others
12.3 Atrial Fibrillation Market (2018-2034) by End User
12.3.1 Market Overview
12.3.2 Hospitals
12.3.3 Specialty Clinics
12.3.4 Others
12.4 Atrial Fibrillation Market (2018-2034) by Distribution Channel
12.4.1 Market Overview
12.4.2 Hospital Pharmacies
12.4.3 Online Pharmacies
12.4.4 Retail Pharmacies
12.5 Atrial Fibrillation Market (2018-2034) by Region
12.5.1 Market Overview
12.5.2 United States
12.5.3 United Kingdom
12.5.4 Germany
12.5.5 France
12.5.6 Italy
12.5.7 Spain
12.5.8 Japan
12.5.9 India
13 United States Atrial Fibrillation Market (218-2034)
13.1 United States Atrial Fibrillation Market (2018-2034) by Treatment Type
13.1.1 Market Overview
13.1.2 Pharmacological Treatment
13.1.2.1 Anticoagulants
13.1.2.2 Antiarrhythmic Drugs
13.1.3 Non-Pharmacological Treatment
13.1.3.1 Catheter Ablation
13.1.3.1.1 Radiofrequency
13.1.3.1.2 HIFU
13.1.3.1.3 Cryoablation
13.1.3.1.4 Microwave
13.1.3.1.5 Laser
13.1.3.2 Maze Surgery
13.1.3.3 Electric Cardioversion
13.2 United States Atrial Fibrillation Market (2018-2034) by Route of Administration
13.2.1 Market Overview
13.2.2 Oral
13.2.3 Intravenous
13.2.4 Others
13.3 United States Atrial Fibrillation Market (2018-2034) by End User
13.3.1 Market Overview
13.3.2 Hospitals
13.3.3 Specialty Clinics
13.3.4 Others
13.4 United States Atrial Fibrillation Market (2018-2034) by Distribution Channel
13.4.1 Market Overview
13.4.2 Hospital Pharmacies
13.4.3 Online Pharmacies
13.4.4 Retail Pharmacies
14 United Kingdom Atrial Fibrillation Market (218-2034)
14.1 United Kingdom Atrial Fibrillation Market (2018-2034) by Treatment Type
14.1.1 Market Overview
14.1.2 Pharmacological Treatment
14.1.2.1 Anticoagulants
14.1.2.2 Antiarrhythmic Drugs
14.1.3 Non-Pharmacological Treatment
14.1.3.1 Catheter Ablation
14.1.3.1.1 Radiofrequency
14.1.3.1.2 HIFU
14.1.3.1.3 Cryoablation
14.1.3.1.4 Microwave
14.1.3.1.5 Laser
14.1.3.2 Maze Surgery
14.1.3.3 Electric Cardioversion
14.2 United Kingdom Atrial Fibrillation Market (2018-2034) by Route of Administration
14.2.1 Market Overview
14.2.2 Oral
14.2.3 Intravenous
14.2.4 Others
14.3 United Kingdom Atrial Fibrillation Market (2018-2034) by End User
14.3.1 Market Overview
14.3.2 Hospitals
14.3.3 Specialty Clinics
14.3.4 Others
14.4 United Kingdom Atrial Fibrillation Market (2018-2034) by Distribution Channel
14.4.1 Market Overview
14.4.2 Hospital Pharmacies
14.4.3 Online Pharmacies
14.4.4 Retail Pharmacies
15 Germany Atrial Fibrillation Market (218-2034)
15.1 Germany Atrial Fibrillation Market (2018-2034) by Treatment Type
15.1.1 Market Overview
15.1.2 Pharmacological Treatment
15.1.2.1 Anticoagulants
15.1.2.2 Antiarrhythmic Drugs
15.1.3 Non-Pharmacological Treatment
15.1.3.1 Catheter Ablation
15.1.3.1.1 Radiofrequency
15.1.3.1.2 HIFU
15.1.3.1.3 Cryoablation
15.1.3.1.4 Microwave
15.1.3.1.5 Laser
15.1.3.2 Maze Surgery
15.1.3.3 Electric Cardioversion
15.2 Germany Atrial Fibrillation Market (2018-2034) by Route of Administration
15.2.1 Market Overview
15.2.2 Oral
15.2.3 Intravenous
15.2.4 Others
15.3 Germany Atrial Fibrillation Market (2018-2034) by End User
15.3.1 Market Overview
15.3.2 Hospitals
15.3.3 Specialty Clinics
15.3.4 Others
15.4 Germany Atrial Fibrillation Market (2018-2034) by Distribution Channel
15.4.1 Market Overview
15.4.2 Hospital Pharmacies
15.4.3 Online Pharmacies
15.4.4 Retail Pharmacies
16 France Atrial Fibrillation Market (218-2034)
16.1 France Atrial Fibrillation Market (2018-2034) by Treatment Type
16.1.1 Market Overview
16.1.2 Pharmacological Treatment
16.1.2.1 Anticoagulants
16.1.2.2 Antiarrhythmic Drugs
16.1.3 Non-Pharmacological Treatment
16.1.3.1 Catheter Ablation
16.1.3.1.1 Radiofrequency
16.1.3.1.2 HIFU
16.1.3.1.3 Cryoablation
16.1.3.1.4 Microwave
16.1.3.1.5 Laser
16.1.3.2 Maze Surgery
16.1.3.3 Electric Cardioversion
16.2 France Atrial Fibrillation Market (2018-2034) by Route of Administration
16.2.1 Market Overview
16.2.2 Oral
16.2.3 Intravenous
16.2.4 Others
16.3 France Atrial Fibrillation Market (2018-2034) by End User
16.3.1 Market Overview
16.3.2 Hospitals
16.3.3 Specialty Clinics
16.3.4 Others
16.4 France Atrial Fibrillation Market (2018-2034) by Distribution Channel
16.4.1 Market Overview
16.4.2 Hospital Pharmacies
16.4.3 Online Pharmacies
16.4.4 Retail Pharmacies
17 Italy Atrial Fibrillation Market (218-2034)
17.1 Italy Atrial Fibrillation Market (2018-2034) by Treatment Type
17.1.1 Market Overview
17.1.2 Pharmacological Treatment
17.1.2.1 Anticoagulants
17.1.2.2 Antiarrhythmic Drugs
17.1.3 Non-Pharmacological Treatment
17.1.3.1 Catheter Ablation
17.1.3.1.1 Radiofrequency
17.1.3.1.2 HIFU
17.1.3.1.3 Cryoablation
17.1.3.1.4 Microwave
17.1.3.1.5 Laser
17.1.3.2 Maze Surgery
17.1.3.3 Electric Cardioversion
17.2 Italy Atrial Fibrillation Market (2018-2034) by Route of Administration
17.2.1 Market Overview
17.2.2 Oral
17.2.3 Intravenous
17.2.4 Others
17.3 Italy Atrial Fibrillation Market (2018-2034) by End User
17.3.1 Market Overview
17.3.2 Hospitals
17.3.3 Specialty Clinics
17.3.4 Others
17.4 Italy Atrial Fibrillation Market (2018-2034) by Distribution Channel
17.4.1 Market Overview
17.4.2 Hospital Pharmacies
17.4.3 Online Pharmacies
17.4.4 Retail Pharmacies
18 Spain Atrial Fibrillation Market (218-2034)
18.1 Spain Atrial Fibrillation Market (2018-2034) by Treatment Type
18.1.1 Market Overview
18.1.2 Pharmacological Treatment
18.1.2.1 Anticoagulants
18.1.2.2 Antiarrhythmic Drugs
18.1.3 Non-Pharmacological Treatment
18.1.3.1 Catheter Ablation
18.1.3.1.1 Radiofrequency
18.1.3.1.2 HIFU
18.1.3.1.3 Cryoablation
18.1.3.1.4 Microwave
18.1.3.1.5 Laser
18.1.3.2 Maze Surgery
18.1.3.3 Electric Cardioversion
18.2 Spain Atrial Fibrillation Market (2018-2034) by Route of Administration
18.2.1 Market Overview
18.2.2 Oral
18.2.3 Intravenous
18.2.4 Others
18.3 Spain Atrial Fibrillation Market (2018-2034) by End User
18.3.1 Market Overview
18.3.2 Hospitals
18.3.3 Specialty Clinics
18.3.4 Others
18.4 Spain Atrial Fibrillation Market (2018-2034) by Distribution Channel
18.4.1 Market Overview
18.4.2 Hospital Pharmacies
18.4.3 Online Pharmacies
18.4.4 Retail Pharmacies
19 Japan Atrial Fibrillation Market (218-2034)
19.1 Japan Atrial Fibrillation Market (2018-2034) by Treatment Type
19.1.1 Market Overview
19.1.2 Pharmacological Treatment
19.1.2.1 Anticoagulants
19.1.2.2 Antiarrhythmic Drugs
19.1.3 Non-Pharmacological Treatment
19.1.3.1 Catheter Ablation
19.1.3.1.1 Radiofrequency
19.1.3.1.2 HIFU
19.1.3.1.3 Cryoablation
19.1.3.1.4 Microwave
19.1.3.1.5 Laser
19.1.3.2 Maze Surgery
19.1.3.3 Electric Cardioversion
19.2 Japan Atrial Fibrillation Market (2018-2034) by Route of Administration
19.2.1 Market Overview
19.2.2 Oral
19.2.3 Intravenous
19.2.4 Others
19.3 Japan Atrial Fibrillation Market (2018-2034) by End User
19.3.1 Market Overview
19.3.2 Hospitals
19.3.3 Specialty Clinics
19.3.4 Others
19.4 Japan Atrial Fibrillation Market (2018-2034) by Distribution Channel
19.4.1 Market Overview
19.4.2 Hospital Pharmacies
19.4.3 Online Pharmacies
19.4.4 Retail Pharmacies
20 India Atrial Fibrillation Market (218-2034)
20.1 India Atrial Fibrillation Market (2018-2034) by Treatment Type
20.1.1 Market Overview
20.1.2 Pharmacological Treatment
20.1.2.1 Anticoagulants
20.1.2.2 Antiarrhythmic Drugs
20.1.3 Non-Pharmacological Treatment
20.1.3.1 Catheter Ablation
20.1.3.1.1 Radiofrequency
20.1.3.1.2 HIFU
20.1.3.1.3 Cryoablation
20.1.3.1.4 Microwave
20.1.3.1.5 Laser
20.1.3.2 Maze Surgery
20.1.3.3 Electric Cardioversion
20.2 India Atrial Fibrillation Market (2018-2034) by Route of Administration
20.2.1 Market Overview
20.2.2 Oral
20.2.3 Intravenous
20.2.4 Others
20.3 India Atrial Fibrillation Market (2018-2034) by End User
20.3.1 Market Overview
20.3.2 Hospitals
20.3.3 Specialty Clinics
20.3.4 Others
20.4 India Atrial Fibrillation Market (2018-2034) by Distribution Channel
20.4.1 Market Overview
20.4.2 Hospital Pharmacies
20.4.3 Online Pharmacies
20.4.4 Retail Pharmacies
21 Regulatory Framework
21.1 Regulatory Overview
21.2 US FDA
21.3 EU EMA
21.4 Japan PMDA
21.5 India CDSCO
21.6 Others
22 Patent Analysis
22.1 Analysis by Type of Patent
22.2 Analysis by Publication Year
22.3 Analysis by Issuing Authority
22.4 Analysis by Patent Age
22.5 Analysis by CPC Analysis
22.6 Analysis by Patent Valuation
23 Clinical Trials Analysis
23.1 Analysis by Trial Registration Year
23.2 Analysis by Trial Status
23.3 Analysis by Trial Phase
23.4 Analysis by Therapeutic Area
23.5 Analysis by Geography
24 Grants Analysis
24.1 Analysis by Year
24.2 Analysis by Amount Awarded
24.3 Analysis by Issuing Authority
24.4 Analysis by Grant Application
24.5 Analysis by Funding Institute
24.6 Analysis by NIH Departments
24.7 Analysis by Recipient Organization
25 Funding and Investment Analysis
25.1 Analysis by Funding Instances
25.2 Analysis by Drug Class of Funding
25.3 Analysis by Funding Amount
25.4 Analysis by Leading Players
25.5 Analysis by Leading Investors
25.6 Analysis by Geography
26 Strategic Initiatives
26.1 Analysis by Partnership Instances
26.2 Analysis by Drug Class of Partnership
26.3 Analysis by Leading Players
26.4 Analysis by Geography
27 Supplier Landscape
27.1 Market Share Analysis, By Region (Top 5 Companies)
27.2 AtriCure Inc.
27.2.1 Financial Analysis
27.2.2 Product Portfolio
27.2.3 Demographic Reach and Achievements
27.2.4 Company News and Development
27.2.5 Certifications
27.3 Boehringer Ingelheim GmbH
27.3.1 Financial Analysis
27.3.2 Product Portfolio
27.3.3 Demographic Reach and Achievements
27.3.4 Company News and Development
27.3.5 Certifications
27.4 Boston Scientific Corporation
27.4.1 Financial Analysis
27.4.2 Product Portfolio
27.4.3 Demographic Reach and Achievements
27.4.4 Company News and Development
27.4.5 Certifications
27.5 Bristol- Myers Squibb Corporation
27.5.1 Financial Analysis
27.5.2 Product Portfolio
27.5.3 Demographic Reach and Achievements
27.5.4 Company News and Development
27.5.5 Certifications
27.6 Cardio Focus Inc.
27.6.1 Financial Analysis
27.6.2 Product Portfolio
27.6.3 Demographic Reach and Achievements
27.6.4 Company News and Development
27.6.5 Certifications
27.7 Sanofi
27.7.1 Financial Analysis
27.7.2 Product Portfolio
27.7.3 Demographic Reach and Achievements
27.7.4 Company News and Development
27.7.5 Certifications
27.8 Biosense Webster Inc.
27.8.1 Financial Analysis
27.8.2 Product Portfolio
27.8.3 Demographic Reach and Achievements
27.8.4 Company News and Development
27.8.5 Certifications
27.9 Abbott
27.9.1 Financial Analysis
27.9.2 Product Portfolio
27.9.3 Demographic Reach and Achievements
27.9.4 Company News and Development
27.9.5 Certifications
27.10 Johnsons & Johnson Services, Inc.
27.10.1 Financial Analysis
27.10.2 Product Portfolio
27.10.3 Demographic Reach and Achievements
27.10.4 Company News and Development
27.10.5 Certifications
27.11 Bayer AG
27.11.1 Financial Analysis
27.11.2 Product Portfolio
27.11.3 Demographic Reach and Achievements
27.11.4 Company News and Development
27.11.5 Certifications
28 Atrial Fibrillation Market - Distribution Model (Additional Insight)
28.1 Overview
28.2 Potential Distributors
28.3 Key Parameters for Distribution Partner Assessment
29 Key Opinion Leaders (KOL) Insights (Additional Insight)
30 Payment Methods (Additional Insight)
30.1 Government Funded
30.2 Private Insurance
30.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security